For U.S. Healthcare Professionals Only

Visit Sanofi U.S.:

The Fabry Registry, a program sponsored and administered by Sanofi Genzyme, was created in 2001 to gather information to improve the understanding and evaluate the treatment of Fabry disease. It is the largest patient registry dedicated to Fabry disease.

Because Fabry disease is rare, it can be difficult to collect information on how the disease and its treatment affect different people. The Fabry Registry is a global, observational database for gathering this critical information. All people who have Fabry disease are eligible to participate, regardless of whether they are on treatment.

For more information on The Fabry Registry, visit our website at


Last Updated: Mar 7, 2019